Cover Image

Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis

Saved in:

Bibliographic Details
Main Authors:	Camille M Powers (Author), Andrew K Yang (Author), Hannah Verma (Author), Jeremy Orloff (Author), Austin J Piontkowski (Author), Nicholas Gulati (Author)
Format:	Book
Published:	JMIR Publications, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022)

Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab
by: Jeremy Orloff, BA, et al.
Published: (2024)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021)

Nivolumab-associated cutaneous T-cell lymphoma
by: Jennifer A. Marks, MD, et al.
Published: (2021)

Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
by: Stefan Milutinovic, et al.
Published: (2024)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020)

Sarilumab‐induced cutaneous adverse event
by: Sayaka Sato, et al.
Published: (2022)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023)

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
by: Mathew R. Birnbaum, BS, et al.
Published: (2017)

A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies
by: Emily D. Nguyen, et al.
Published: (2020)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab
by: Dimitrii Pogorelov, et al.
Published: (2024)

The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study
by: Jade N. Young, BS, et al.
Published: (2024)

Adverse events attributed to traditional Korean medical practices: 1999-2010
by: Hyeun-Kyoo Shin, et al.
Published: (2013)

Nivolumab-induced oral and cutaneous bullous pemphigoid: A case report
by: Sturque Julie, et al.
Published: (2019)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
by: Kenneth Thomsen, et al.
Published: (2018)

Investigation of Public Acceptance of Misinformation Correction in Social Media Based on Sentiment Attributions: Infodemiology Study Using Aspect-Based Sentiment Analysis
by: Ning Ma, et al.
Published: (2024)

Vemurafenib and cutaneous adverse events - report of five cases
by: Giselle de Barros Silva, et al.
Published: (2015)

Cutaneous Adverse Events After COVID-19 Vaccination
by: Weschawalit S, et al.
Published: (2023)

A Sentimental Education
by: McGregor, Hannah
Published: (2022)

No-fault compensation following adverse events attributed to vaccination: a review of international programmes
by: Clare Looker, et al.
Published: (2011)

Análise das notas técnicas do Núcleo de Apoio ao Judiciário da Bahia (NATJUS - BA) para os medicamentos Atezolizumabe; Nivolumabe e Pembrolizumabe.
by: Pedro Paulo Ribeiro Silva Cunha, et al.
Published: (2023)

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database
by: Yilun Li, et al.
Published: (2024)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021)

Adverse Drug Reaction Related Post Detecting Using Sentiment Feature
by: Jingfang LIU, et al.
Published: (2018)

Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab‐induced bullous pemphigoid
by: Shin Iinuma, et al.
Published: (2023)

A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma
by: Shohei Igari, et al.
Published: (2024)

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma
by: Edouard Chasseuil, et al.
Published: (2018)

Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect
by: Aditi Bansal, et al.
Published: (2023)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021)

Photosensitive rash induced by nivolumab
by: Francisco J. Navarro-Triviño, et al.
Published: (2022)

Nivolumab-Induced Thyroid Dysfunction
by: Lohit Kumbar, et al.
Published: (2021)

In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database
by: Kaori Ambe, et al.
Published: (2021)

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
by: Nicoletta Colombo, et al.
Published: (2023)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022)